help button home button Endocrine Society Molecular Endocrinology ENDO 08 Sessions Library
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on June 19, 2007
Molecular Endocrinology, doi:10.1210/me.2006-0452
A more recent version of this article appeared on September 1, 2007
This Article
Right arrow Author Manuscript (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
21/9/2124    most recent
Author Manuscript (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wiper-Bergeron, N.
Right arrow Articles by Lee, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wiper-Bergeron, N.
Right arrow Articles by Lee, J. M.

Submitted on October 31, 2006
Accepted on June 11, 2007

C/EBP{beta} abrogates retinoic acid-induced osteoblast differentiation via repression of Runx2 transcription

Nadine Wiper-Bergeron*, Catherine St-Louis, and Jonathan M. Lee

Department of Cellular and Molecular Medicineand Department of Biochemistry, Microbiology and Immunology, University of Ottawa, 451 Smyth Road, Ottawa, Ontario, Canada, K1H 8M5

* To whom correspondence should be addressed. E-mail: Nadine.WiperBergeron{at}uottawa.ca.

Runx2/CBFA1/AML3 is a master regulator of the osteoblast lineage and has been shown to directly control the transcription of numerous osteoblast specific genes including alkaline phosphatase, osteopontin and type I collagen. In its absence, ossification does not occur during development resulting in animals with cartilaginous skeletons and no osteoblasts. In humans, loss of one copy of Runx2 causes cleidocranial dysplasia characterized by malformations of the facial and cranial bones and the clavicle. Despite its important role in osteoblast biology, relatively little is known about the transcriptional regulation of the Runx2 gene. In the present study, we show that CCAAT/enhancer binding protein {beta} (C/EBP{beta}) is a negative regulator of Runx2 expression and acts by directly binding a C/EBP element located at -591/-576 within the osteoblast-specific Runx2 P1 promoter. Ectopic expression of C/EBP{beta} in C3H10T1/2 cells causes a reduction in Runx2 expression concomitant with a decrease in osteogenic potential during all-trans retinoic acid (ATRA)-induced differentiation. In non-differentiating cells, C/EBP{beta} can be found occupying the C/EBP negative response element within the Runx2 P1 promoter. ATRA, the effects of which are mediated by RAR{alpha} and RAR{gamma} in C3H10T1/2 cells, stimulates the dissociation of C/EBP{beta} from this element and promotes Runx2 expression. Thus, ATRA initiates osteoblastic differentiation of C3H10T1/2 cells, at least in part, by triggering the dissociation of C/EBP{beta} from the Runx2 promoter.


Key words: CCAAT-Enhancer binding protein-beta • Core binding factor Alpha 1 subunit • osteoblast differentiation • Gene expression • Transcription repression







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2007 by The Endocrine Society